Pr Jean Rivest, M.D.Professeur titulaire |
Service de neurologie Département de médecine Faculté de médecine et des sciences de la santé Université de Sherbrooke 3001, 12e Avenue Nord Sherbrooke (Québec) J1H 5N4 Téléphone : 819 821-8000, poste 70270 Télécopieur : 819 564-5395 Courriel : Jean.Rivest@USherbrooke.ca |
Chercheur principal : Rivest J
Organisme commanditaire :
Allergan inc.
Chercheur principal : Rivest J
Organisme commanditaire :
Merck Canada inc.
Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts.
Marras C, McDermott MP, Marek K, Rochon P, Naglie G, Tanner CM, Rudolph A, Shoulson I, Lang AE; Parkinson Study Group DATATOP and PRECEPT investigators (Rivest J).
Mov Disord. 2011 Mar;26(4):608-13. doi: 10.1002/mds.23581. Epub 2011 Feb 1. PMID: 21287602
Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease.
Schwid SR, Bausch J, Oakes D, Schuchter L, Tanner C, Forrest M, Lang AE, Shoulson I; PSG PRECEPT Investigators (Rivest J), Shoulson I, Hyson C, Oakes D, Flagg E, Rudolph A, Kieburtz K, Lang A, Fahn S, Gauger L, Goetz C.
Mov Disord. 2010 Sep 15;25(12):1801-8. PMID: 20669311
A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts.
Marras C, Lang AE, Eberly SW, Oakes D, Fahn S, Schwid SR, Hyson C, Shoulson I; Parkinson Study Group DATATOP and PRECEPT investigators (Rivest J).
Mov Disord. 2009 Dec 15;24(16):2370-8. PMID: 19908310
Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease.
Hauser RA, Panisset M, Abbruzzese G, Mancione L, Dronamraju N, Kakarieka A; FIRST-STEP Study Group (Rivest J).
Mov Disord. 2009 Mar 15;24(4):541-50. PMID: 19058133